Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 He will also establish a U.S. clinical and research site to complement the company's research...
XtalPi Debuts Kodexia™, the World's First Closed-Loop siRNA Platform Combining Generative AI with First-Principles Modeling
This unified platform integrates sequence design, chemical modification, experimental validation, extrahepatic delivery design, and intellectual property strategy into an integrated computational–experimental workflow, pioneering in vivo efficacy...
XtalPi and Fangda Carbon Deploy Predictive AI to Optimize Cost and Material Efficiency in Graphite Electrode Manufacturing
The jointly developed AI model has passed comprehensive acceptance testing and is now operating within Fangda Carbon's production workflow. By forecasting performance and screening formulations before physical trials, the system meets cost...
XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain
This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's AI and robotics-driven drug discovery platform and its transition to a clinical-stage organization....
XtalPi AI Enables Seven-Month PCC Nomination for Viva-Thera's MPER-Targeting HIV-1 Program
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Thera combines its first atomic-resolution MPER-TMD-CT structure with XtalPi's AI and automation...
XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international...
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies
BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial...
XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway
SHENZHEN, China, May 4, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5...
Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading...
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. Cross-sector...